Clinical trials: Autoinflammatory Syndrome
Mevalonate Kinase Deficiency
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway.
- Trial name
- NCT06497829
- Testing
- geranylgeraniol
- Where
- Czechia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Motol
Immunodeficiency, Autoimmune Diseases
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system…
- Conditions
- Immunodeficiency, Autoimmune Diseases, Autoinflammatory Syndrome, Allergy
- Trial name
- SAID (NCT06248957)
- Testing
- Immunomodulation
- Where
- Sweden
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Cryopyrin-Associated Periodic Syndromes
Kineret CAPS Post Authorisation Study
A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies…
- Trial name
- NCT02326376
- Testing
- anakinra (Kineret)
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Swedish Orphan Biovitrum
Cryopyrin-Associated Periodic Syndromes (CAPS)
HL2351 CAPS Phase II Study
This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).
- Trial name
- NCT02853084
- Testing
- HL2351
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Handok Inc.
DIRA
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Background: Deficiency of the IL-1 receptor antagonist (DIRA) is a condition that causes repeated episodes of inflammation. People with DIRA can have rashes, fever, and joint pain.
- Trial name
- NCT01801449
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Autoimmune Encephalitis, Early-stage Panencephalitis
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including…
- Conditions
- Autoimmune Encephalitis, Early-stage Panencephalitis, Neuroinflammatory Demyelination
- Trial name
- NCT07145502
- Testing
- Allogeneic MSC infusions (IV)
- Where
- Poland
- Volunteers
- 76 people
- Sponsor
- Biocells Medical
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This will provided long-term safety and efficacy data for ACZ885 (a fully human anti-interleukin-1β [anti-IL-1β] monoclonal antibody) given as an injection subcutaneously in patients who participated in the CACZ885A2102…
- Conditions
- Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT00685373
- Testing
- Canakinumab (ACZ885)
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- Novartis
Sarcoidosis, Tuberculosis
The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis
This study evaluates the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases.
- Trial name
- uveitis (NCT02627209)
- Testing
- spectrophotometric assay, radial immunodiffusion
- Where
- Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Ozlem Sahin
VEXAS Syndome, Autoinflammatory Disease
Autoimmune and Autoinflammatory Genetics Study
This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of…
- Conditions
- VEXAS Syndome, Autoinflammatory Disease, Autoimmune Disease, Rheumatic Disease
- Trial name
- NCT06004349
- Where
- 2 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Behcet Disease
Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle Trianing
physical complications are common in Behcet disease patients with pulmonary endoarterectomy, so outcomes of program of inspiratory msucle trianing must be investigated
- Trial name
- NCT07662603
- Testing
- inspiratory muscle trianing
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
NOMID, CINCA Syndrome
Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
This study will examine whether a medicine called canakinumab is safe and effective for treating patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous…
- Trial name
- NCT00770601
- Testing
- Canakinumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Behcet's Disease, Vasculitis
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
Behçet's disease (BD) is a systemic vasculitis of arterial and venous vessels of any size, involving young patients (from 15 to 45 years). BD significantly increases morbidity and mortality.
- Trial name
- ITAC (NCT03371095)
- Testing
- Infliximab, Cyclophosphamide
- Where
- 27 sites in France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hereditary Autoinflammatory Disease
Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)
This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to assess the effects and safety of Lanadelumab in patients with FXII-associated cold autoinflammatory syndrome (FACAS).
- Trial name
- LANA-FXII (NCT04278885)
- Testing
- Lanadelumab
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Charite University, Berlin, Germany
Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS)
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.
- Conditions
- Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS), Muckle-wells Syn (MWS), Neonatal Onset Multisystem Inflam Disease (NOMID)
- Trial name
- B-Confident (NCT01213641)
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 288 people
- Sponsor
- Novartis Pharmaceuticals
Behcet's Disease, Uveitis
Immunogenetic Mechanisms in Behcet's Disease
Background: Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases of legal blindness every year.
- Trial name
- NCT01109433
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Eye Institute (NEI)
Cryopyrin Associated Periodic Syndrome
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
This study will assess the safety, tolerability and efficacy of canakinumab treatment in Canadian patient diagnosed with cryopyrin-associated periodic syndrome over a period of 18 months.
- Trial name
- NCT01105507
- Testing
- canakinumab (company code: ACZ885D)
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Behcet's Disease
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1.
- Trial name
- NCT01960790
- Volunteers
- 473 people
- Sponsor
- AbbVie
Mevalonate Kinase Deficiency
Canakinumab in Patients With Active Hyper-IgD Syndrome
This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics (PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.
- Trial name
- NCT01303380
- Testing
- Canakinumab
- Where
- 3 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
NALP3 Mutation
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients with NALP3 mutations whose clinical symptoms are…
- Trial name
- NCT00487708
- Testing
- canakinumab
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome
Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome
The goal of this clinical trial is to evaluate the efficacy and safety of thalidomide in the treatment of children with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) syndrome.
- Trial name
- NCT07476625
- Testing
- Thalidomide (50mg), Colchicine
- Volunteers
- 106 people
- Sponsor
- Wenjie Zheng